1-[3-叔丁基苯基]肼盐酸盐 | 306937-27-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-[3-叔丁基苯基]肼盐酸盐
• 英文名称: 3-(t-butyl)phenylhydrazine hydrochloride
• 英文别名: (3-tert-butyl-phenyl)-hydrazine; hydrochloride；(3-tert-Butyl-phenyl)-hydrazin; Hydrochlorid；(3-Tert-butylanilino)azanium;chloride
• CAS: 306937-27-9
• 化学式: C₁₀H₁₆N₂*ClH
• mdl: MFCD00833404
• 分子量: 200.711
• InChiKey: XKLKKAKHNGXDPA-UHFFFAOYSA-N

物化性质

• 熔点：
  146 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.91
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  39.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2928000090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P201,P202,P261,P264,P270,P271,P272,P273,P280,P301+P310+P330,P302+P352+P312,P304+P340+P311,P308+P313,P333+P313,P391,P403+P233,P405,P501
• 危险品运输编号：
  2811
• 危险性描述：
  H301+H311+H331,H317,H350,H410

反应信息

• 作为反应物：
  描述：

  5-甲氧基靛红 、 1-[3-叔丁基苯基]肼盐酸盐 以 甲醇 为溶剂， 以100%的产率得到(3Z)-5-methoxy-1H-indole-2,3-dione 3-[(3-tert-butylphenyl)hydrazone]
  参考文献：
  名称：

  Synthesis and biophysical evaluation of arylhydrazono-1H-2-indolinones as β-amyloid aggregation inhibitors

  摘要：

  A series of isatin-3-arylhydrazones were synthesized and evaluated in vitro as inhibitors of A beta(1-40) aggregation using a thioflavin T fluorescence method. An exploration of the effects on A beta(1-40) aggregation of a number of diverse substituents at phenylhydrazone group and 5,6- positions of the indolinone nucleus led us to single out some new anti-aggregating compounds with IC50 values in the low micromolar range. The most active compounds carry methoxy- or hydroxy- substituents in the indolinone 5,6-positions and lipophilic groups such as iPr and Cl at 4'- and 3'-position, respectively, of the phenylhydrazone moiety. Two derivatives are noteworthy, namely 18 (IC50 = 0.4 mu M) and 42 (IC50 = 1.1 mu M). The in vitro effects of the highly active, water soluble, compound 42 on the temporal evolution of A beta(1-40) fibrils formation were further investigated by circular dichroism spectroscopy, transmission electron microscopy and dynamic light scattering studies, which clearly showed that this compound delayed and lowered the amyloid fibril formation. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.11.015

文献信息

• Thrombopoietin mimetics
  申请人：——

  公开号：US20040019190A1

  公开（公告）日：2004-01-29

  Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy- 1 -azobenzene derivative.

  发明了非肽类TPO类似物。还发明了用于制备目前发明的化合物的新工艺和中间体。还发明了一种治疗血小板减少症的方法，包括给予需要的哺乳动物，包括人类，有效量的选择性羟基-1-偶氮苯衍生物。
• Asymmetric Synthesis of Tetracyclic Pyrroloindolines and Constrained Tryptamines by a Switchable Cascade Reaction
  作者：Corien de Graaff、Lisa Bensch、Sjoerd J. Boersma、Răzvan C. Cioc、Matthijs J. van Lint、Elwin Janssen、Nicholas J. Turner、Romano V. A. Orru、Eelco Ruijter

  DOI：10.1002/anie.201507041

  日期：2015.11.16

  The interrupted Fischer indole synthesis of arylhydrazines and biocatalytically generated chiral bicyclic imines selectively affords either tetracyclic pyrroloindolines or tricyclic tryptamine analogues depending on the reaction conditions. We demonstrate that the reaction is compatible with a variety of functional groups. The products are obtained in high optical purity and in reasonable to good yield

  芳基肼的费歇尔吲哚合成中断和生物催化产生的手性双环亚胺选择性地提供四环吡咯并吲哚啉或三环色胺类似物，具体取决于反应条件。我们证明该反应与多种官能团相容。获得的产品具有高的光学纯度，并且具有合理至良好的产率。我们提出了一个合理的反应机理来解释所观察到的反应结果，具体取决于酸介体的化学计量。为了证明我们方法的合成实用性，在高效反应序列中合成了两种产品类别的药物相关实例，包括酚丝氨酸类似物作为潜在的胆碱酯酶抑制剂，而约束性色胺衍生物作为5-HT的选择性抑制剂。6血清素受体和TRPV1离子通道。
• DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
  申请人：Bolin David Robert

  公开号：US20090076275A1

  公开（公告）日：2009-03-19

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供了式(I)的化合物，以及其药用盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗疾病如肥胖、II型糖尿病和代谢综合征等方面是有用的。
• THROMBOPOIETIN MIMETICS
  申请人：Duffy Kevin J.

  公开号：US20130078213A1

  公开（公告）日：2013-03-28

  Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

  本发明涉及非肽类TPO类似物的发明。本发明还涉及用于制备目前发明的化合物的新型过程和中间体。本发明还涉及一种治疗血小板减少症的方法，包括在需要的哺乳动物（包括人类）中给予所选的羟基-1-偶氮苯衍生物的有效量。
• [EN] DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS<br/>[FR] INHIBITEURS DE LA DIACYLGLYCÉROL ACYLTRANSFÉRASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009037222A1

  公开（公告）日：2009-03-26

  Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.